Impact of cabozantinib on plasma adrenocorticotropic hormone and serum cortisol concentrations in individuals with metastatic renal cell carcinoma: a retrospective analysis - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Impact of cabozantinib on plasma adrenocorticotropic hormone and serum cortisol concentrations in individuals with metastatic renal cell carcinoma: a retrospective analysis
Clinical Scorecard: Impact of cabozantinib on plasma adrenocorticotropic hormone and serum cortisol concentrations in individuals with metastatic renal cell carcinoma: a retrospective analysis
At a Glance
Category
Detail
Condition
Key Mechanisms
Cabozantinib (CABO) as a TKI may induce primary adrenal insufficiency (PAI) through mechanisms affecting adrenal function and hormone regulation.
Target Population
Care Setting
Key Highlights
Cabozantinib may cause primary adrenal insufficiency in mRCC patients, as evidenced by clinical studies.
Monitoring of plasma ACTH and serum cortisol levels is crucial for early detection of adrenal insufficiency, supported by recent findings.
Fatigue and appetite loss are common symptoms associated with TKI-induced PAI; further studies indicate prevalence rates.
Guideline-Based Recommendations
Diagnosis
Management
Consider glucocorticoid replacement therapy for patients diagnosed with PAI, and provide detailed dosing guidelines.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients may experience fatigue and other symptoms requiring close monitoring and possible glucocorticoid therapy adjustments.
Clinical Best Practices
Conduct routine monitoring for adrenal function in patients receiving TKIs, ideally every 4-6 weeks during treatment.
